Admin Core
管理核心
基本信息
- 批准号:10598770
- 负责人:
- 金额:$ 28.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS related cancerAddressAfricaAfrica South of the SaharaAfricanBiological MarkersCancer CenterCaringChronic DiseaseClimateClinicalCollaborationsCommunicationComplexCountryDetectionDevelopmentDiagnosisDiagnosticDiseaseEnsureEnvironmentGoalsGroup MeetingsHIVHIV-1Health SciencesHospitalsHuman Herpesvirus 8Immune responseImmunologicsImmunosuppressionIndividualInformation DisseminationInfrastructureInstitutionInternationalKaposi SarcomaLeadershipLocationLouisianaMalignant NeoplasmsMissionOceansOutcomeOutcomes ResearchPathogenesisPersonsPilot ProjectsPoliciesPreventionProcessResearchResearch ActivityResearch InfrastructureResearch Project GrantsResource SharingResourcesSeriesTanzaniaTeaching HospitalsTechnologyTissuesTrainingUnited StatesUnited States National Institutes of HealthUniversitiesViralViral reservoirVirus LatencyWorkZambiaanticancer researchantiretroviral therapycareer developmentdata disseminationdata integrationdata managementdata sharingdesignexperienceimprovedmeetingsmetabolomicspreventprogramssuccesssynergism
项目摘要
A multi-institutional, international, and integrated endeavor, the “KS in the Era of ART in Africa Program
(KEAAP)” will leverage the research and training expertise of collaborating institutions from the U.S. and two
African countries: the Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), the
Cancer Diseases Hospital (CDH) and the University Teaching Hospitals (UTH) of Zambia, and the Ocean
Road Cancer Institute (ORCI) in Dar es Salaam, Tanzania to form an HIV-Associated Malignancy Research
Center (HAMRC) that focuses on the research gaps of the Kaposi sarcoma (KS) disease. Building on the
success of their previous collaborations, these institutions will synergize their efforts under one overarching
research theme that focuses on the KS disease spectrum, from detection, to care and outcomes, to
deciphering KS pathogenesis and immune response. The immediate goal is to 1) implement a program to
better integrate KS diagnostic, clinical and research activities within the HIV-1 care and treatment networks in
both countries; 2) define stage- and treatment-associated immunologic and metabolomics biomarkers across
the spectrum of KS disease presentation; and 3) define the magnitude and breadth of Kaposi sarcoma
herpesvirus (KSHV) latent viral reservoirs in tissues of KSHV infected people living with HIV, so that these
reservoirs could be targeted for prevention of viral reactivation to prevent KS. To achieve this goal and promote
synergy and coordination across partnering institutions, KEAAP will establish an Administrative Core, based at
LSUHSC-NO with satellite locations at UTH/CDH, and ORCI, that will provide the administrative support
needed to ensure that KEAAP’s three research projects, Shared Resource Core (Data Management and
Integration Core), and Career Development Core can accomplish their individual and collective goals while
functioning in an integrated and coordinated manner. The Administrative Core will pursue four specific aims.
1) Provide the administrative expertise and resources necessary to support the consortium’s research projects
and cores and the pilot projects to accomplish their goals and specific aims. 2) Implement a consortium-wide
series of operational processes designed to create a collaborative research environment, promote data sharing
and dissemination of results, and build capacity for increased self-sufficiency at cancer research institutions in
Tanzania and Zambia. 3) Provide communications infrastructure to engage key stakeholders, to promote the
consortium, and disseminate information and research outcomes that will inform healthy policy changes locally,
and globally. The organization of the Administrative Core is designed to be responsive, inclusive, and robust –
attributes that are essential to address the broad mission and complex relationships within KEAAP, among
collaborating institutions, and with NIH. The core will focus on meeting the needs of the collaborators in a
climate of rapidly changing scientific and technological advances in order to promote a sustainable consortium
with vibrant research programs that work toward the reduction of cancer in sub-Saharan Africa.
多机构,国际和综合努力,“非洲艺术时代的KS”
(KEAAP)”将利用来自美国和两个的合作机构的研究和培训专业知识
非洲国家:路易斯安那州立大学健康科学中心 - 新奥尔良(LSUHSC-NO),
癌症疾病医院(CDH)和赞比亚的大学教学医院(UTH)和海洋
坦桑尼亚达累斯萨拉姆的公路癌研究所(ORCI)形成了与HIV相关的恶性研究
中心(HAMRC)着重于Kaposi肉瘤(KS)疾病的研究差距。建立在
他们以前合作的成功,这些机构将在一个总体下综合他们的努力
从检测到护理和结果,再到KS疾病范围的研究主题
破译KS发病机理和免疫反应。直接目标是1)实施一个程序
在HIV-1护理和治疗网络中,更好地整合KS诊断,临床和研究活动
两国; 2)定义跨阶段和治疗相关的免疫学和代谢组学生物标志物
KS疾病表现的范围; 3)定义Kaposi肉瘤的大小和广度
疱疹病毒(KSHV)在KSHV感染艾滋病毒的人的组织中潜在病毒储量,以便这些
可以将储层用于预防病毒重新激活以防止KS。实现这一目标并促进
KEAAP将在合作机构之间的协同作用和协调
LSUHSC-NO在UTH/CDH和ORCI的卫星位置,将提供行政支持
需要确保KEAAP的三个研究项目,共享资源核心(数据管理和
集成核心),职业发展核心可以实现其个人和集体目标,同时
以集成和协调的方式运作。行政核心将追求四个具体目标。
1)提供支持财团研究项目所需的行政专业知识和资源
还有核心和试点项目,以实现其目标和特定目标。 2)实施整个财团
一系列旨在创建协作研究环境,促进数据共享的运营过程
并传播结果,并在癌症研究机构中提高自给自足的能力
坦桑尼亚和赞比亚。 3)提供通信基础设施以吸引关键利益相关者,以促进
财团,并传播将在当地为健康政策变化提供信息的信息和研究成果
和全球。行政核心的组织旨在响应迅速,包容和健壮 -
解决KEAAP内部的广泛使命和复杂关系至关重要的属性
协作机构,并与NIH合作。核心将着重于满足合作者的需求
迅速变化的科学和技术进步的气候,以促进可持续财团
借助充满活力的研究计划,致力于减少撒哈拉以南非洲的癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Wood其他文献
Charles Wood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Wood', 18)}}的其他基金
23rd International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents
第23届卡波西肉瘤疱疹病毒(KSHV)及相关病原体国际研讨会
- 批准号:
10525451 - 财政年份:2020
- 资助金额:
$ 28.51万 - 项目类别:
23rd International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents
第23届卡波西肉瘤疱疹病毒(KSHV)及相关病原体国际研讨会
- 批准号:
10754345 - 财政年份:2020
- 资助金额:
$ 28.51万 - 项目类别:
Biomarkers for Dysbiosis-Related HIV-Associated Cognitive Disorders among Persons Who Inject Drugs in Puerto Rico
波多黎各注射吸毒者中与生态失调相关的艾滋病毒相关认知障碍的生物标志物
- 批准号:
10654868 - 财政年份:2019
- 资助金额:
$ 28.51万 - 项目类别:
Biomarkers for Dysbiosis-Related HIV-Associated Cognitive Disorders among Persons Who Inject Drugs in Puerto Rico
波多黎各注射吸毒者中与生态失调相关的艾滋病毒相关认知障碍的生物标志物
- 批准号:
10594192 - 财政年份:2019
- 资助金额:
$ 28.51万 - 项目类别:
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement
赞比亚艾滋病恶性肿瘤诊断和发病机制计划补充资料
- 批准号:
10533536 - 财政年份:2017
- 资助金额:
$ 28.51万 - 项目类别:
The impact of Cannabis on inflammation and HIV-1 reservoirs in Zambia
大麻对赞比亚炎症和 HIV-1 病毒库的影响
- 批准号:
9920695 - 财政年份:2017
- 资助金额:
$ 28.51万 - 项目类别:
The impact of Cannabis on inflammation and HIV-1 reservoirs in Zambia
大麻对赞比亚炎症和 HIV-1 病毒库的影响
- 批准号:
9529608 - 财政年份:2017
- 资助金额:
$ 28.51万 - 项目类别:
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement
赞比亚艾滋病恶性肿瘤诊断和发病机制计划补充资料
- 批准号:
10581802 - 财政年份:2017
- 资助金额:
$ 28.51万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION)
与肿瘤学合作评估艾滋病病毒感染者的病毒和免疫景观交叉点 (PAVILION)
- 批准号:
10598373 - 财政年份:2023
- 资助金额:
$ 28.51万 - 项目类别:
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
- 批准号:
10871931 - 财政年份:2023
- 资助金额:
$ 28.51万 - 项目类别: